Bone Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Bone Cancer, including details on symptoms, types, treatment.

Promiscuous partnerships in Ewing's sarcoma.

Sankar S, Lessnick SL

Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA.

Ewing's sarcoma is a highly aggressive bone and soft tissue tumor of children and young adults. At the molecular genetic level Ewing's sarcoma is characterized by a balanced reciprocal translocation, t(11;22)(q24;q12), which encodes an oncogenic fusion protein and transcription factor EWS/FLI. This tumor-specific chimeric fusion retains the amino terminus of EWS, a member of the TET (TLS/EWS/TAF15) family of RNA-binding proteins, and the carboxy terminus of FLI, a member of the ETS family of transcription factors. In addition to EWS/FLI, variant translocation fusions belonging to the TET/ETS family have been identified in Ewing's sarcoma. These studies solidified the importance of TET/ETS fusions in the pathogenesis of Ewing's sarcoma and have since been used as diagnostic markers for the disease. EWS fusions with non-ETS transcription factor family members have been described in sarcomas that are clearly distinct from Ewing's sarcoma. However, in recent years there have been reports of rare fusions in "Ewing's-like tumors" that harbor the amino-terminus of EWS fused to the carboxy-terminal DNA or chromatin-interacting domains contributed by non-ETS proteins. This review aims to summarize the growing list of fusion oncogenes that characterize Ewing's sarcoma and Ewing's-like tumors and highlights important questions that need to be answered to further support the existing concept that Ewing's sarcoma is strictly a "TET/ETS" fusion-driven malignancy. Understanding the molecular mechanisms of action of the various different fusion oncogenes will provide better insights into the biology underlying this rare but important solid tumor.

Published 29 August 2011 in Cancer Genet, 204(7): 351-65.
Full-text of this article is available online (may require subscription).

Articles on Bone Cancer published 26 August 2011:

Skull base reconstruction: an updated approach.   Plast Reconstr Surg, 128(3): 675-86.

[Abstract] [Full-text]

Osteosarcoma of the jaws: factors influencing prognosis.   J Oral Maxillofac Surg, 69(9): 2368-75.

[Abstract] [Full-text]

Articles on Bone Cancer published 25 August 2011:

Functioning free gracilis myocutaneous flap transfer provides a reliable single-stage facial reconstruction and reanimation following tumor ablation.   Plast Reconstr Surg, 128(3): 687-96.

[Abstract] [Full-text]

Articles on Bone Cancer published 18 August 2011:

Vanishing bone metastases--a pitfall in the interpretation of contrast enhanced CT in patients with superior vena cava obstruction.   Br J Radiol, 84(1005): e176-8.

We describe a previously unreported case of vertebral marrow enhancement owing to collateral circulation in a patient with superior vena cava obstruction. Failure to recognise this phenomenon led to the misdiagnosis of sclerotic bone metastases. [Abstract] [Full-text]

Articles on Bone Cancer published 16 August 2011:

Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma.   Tumour Biol, 32(5): 1013-21.

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. To identify new biomarkers for early diagnosis of OS and novel therapeutic candidates, we carried out a plasma membrane proteomic study based on two-dimensional electrophoresis (2DE). The OS cell line MG-63 and the human osteoblastic cell line hFOB1.19 were adopted as the comparison model. We extracted plasma membrane by aqueous two-phase partition extraction. The proteins were separated through 2DE. ... [Abstract] [Full-text]

Articles on Bone Cancer published 11 August 2011:

Odontogenic tumours manifesting in the first two decades of life in a rural African population sample: a 26 year retrospective analysis.   Dentomaxillofac Radiol, 40(6): 331-7.

[Abstract] [Full-text]

Blastic plasmacytoid dendritic cell neoplasm expressing the CD13 myeloid antigen.   Acta Haematol, 126(2): 122-8.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), currently considered to originate from immature plasmacytoid dendritic cells (DC), is a rare and aggressive CD4+CD56+ neoplasm that frequently involves the skin and bone marrow. We present a case of an 80-year-old man with a CD4+CD56+ BPDCN that affected the orbital cavity and bone marrow. Although BPDCN has not been reported to express any lineage-specific markers, the neoplastic cells strongly expressed the CD13 antigen. Therefore, in ... [Abstract] [Full-text]

Articles on Bone Cancer published 10 August 2011:

Blockade of transforming growth factor-beta (TGFβ) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line.   Prostate, 71(13): 1441-54.

[Abstract] [Full-text]

© 2004-2011 Bone Cancer Research Today. All Rights Reserved.